The Food and Drug Administration (FDA) has approved three GLP-1s for obesity-related treatment, including Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide)
Two of these proteins, interleukin 12 (IL-12) and interleukin 23 (IL-23), have been implicated as important contributors to the chronic inflammation that is a main feature of ulcerative colitis
But what happens when a consumers very ability to feel hunger, indulgence or satisfaction is biologically altered
If side effects are severe (persistent vomiting, signs of pancreatitis, vision changes), stop the medication and contact your prescriber immediately
Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders